Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab vs Placebo in Combination with Cisplatin and 5-FU for First-Line Treatment of Advanced Esophageal Cancer
CTR20171642Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab in esophageal cancer, Esophageal Squamous Cell Carcinoma (ESCC), esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma, sponsored by Merck & Co.. Started Jun 2018; status: completed.
02
Drugs
03
Conditions
esophageal cancerEsophageal Squamous Cell Carcinoma (ESCC)esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20171642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171642.